Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain. It is also used to treat headaches, general back pain, and certain joint pains like arthritis.

It is found in a variety of over-the-counter (OTC) medications as an anti-inflammatory, primarily for back-pain relief. Magnesium Salicylate can be an effective OTC alternative to prescription NSAIDs, with both anti-inflamatory and pain-relieving effects.

Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.

Structure

Similar Structures

Synonyms

Magnesium salicylate
Magnesium salicylate anhydrous

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Magnesium salicylate tetrahydrate	41728CY7UX	18917-95-8	NBQBEWAYWAMLJJ-UHFFFAOYSA-L

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Salicylic acid	unknown	O414PZ4LPZ	69-72-7	YGSDEFSMJLZEOE-UHFFFAOYSA-N

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Arthriten Tablets	Tablet	325 mg	Oral	Alva Amco Pharmacal Companies, Inc.	2003-05-15	2006-07-27
Back-ese M Tab 325mg	Tablet	325 mg	Oral	G.T. Fulford Pharmaceuticals	1985-12-31	1998-06-25
Back-ese M Tablets 325 mg	Tablet	325 mg	Oral	Dannorth Laboratories Inc.	1980-12-31	2000-07-19
Backache Aid	Tablet, film coated	580 mg/1	Oral	L&R Distributors, Inc.	1998-11-07	Not applicable
Backache Relief	Tablet, film coated	580 mg/1	Oral	Rite Aid Corporation	1998-11-07	Not applicable
Backache Relief	Tablet, film coated	580 mg/1	Oral	CVS PHARMACY	1998-11-07	Not applicable
Backache Relief Extra Strength	Tablet	580 mg/1	Oral	Walgreen	1998-11-07	2018-04-10
Backache Relief Extra Strength	Tablet, film coated	580 mg/1	Oral	L.N.K. International, Inc.	1998-11-07	Not applicable
Doan's Backache Pills 325mg	Tablet	325 mg	Oral	Novartis	1988-12-31	1998-07-08
Doans Extra Strength	Tablet	580 mg/1	Oral	Dr. Reddy's Laboratories Inc.	2016-05-24	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Arthriten Joint Pain Relief	Magnesium salicylate tetrahydrate (310 mg/1) + Acetaminophen (250 mg/1) + Caffeine (32.5 mg/1)	Tablet, film coated	Oral	Alva-Amco Pharmacal Companies, Inc.	2002-10-28	2010-05-17
Back Relief	Magnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1)	Tablet	Oral	Honeywell Safety Products USA, Inc	2017-12-20	Not applicable
Back Relief	Magnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1)	Tablet	Oral	Honeywell Safety Products USA, Inc	2013-05-14	2017-12-20
Diurex Water Pills	Magnesium salicylate tetrahydrate (162.5 mg/1) + Caffeine (50 mg/1)	Tablet, coated	Oral	Alva-Amco Pharmacal Companies, Inc.	2005-05-15	Not applicable
MEDIQUE Back Pain Off	Magnesium salicylate tetrahydrate (290 mg/1) + Acetaminophen (250 mg/1) + Caffeine (50 mg/1)	Tablet, film coated	Oral	Unifirst First Aid Corporation	2008-12-30	Not applicable
Otis Clapp Back Quell	Magnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1)	Tablet, film coated	Oral	Unifirst First Aid	2008-12-30	Not applicable
Pain Aid BRF	Magnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1)	Tablet	Oral	Zee Medical Inc	2012-08-19	Not applicable
Pamprin Cramp Menstrual Pain Relief	Magnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1) + Pamabrom (25 mg/1)	Tablet	Oral	Chattem, Inc.	1983-01-01	Not applicable
Trilisate Tab	Magnesium salicylate (362 mg) + Choline salicylate (293 mg)	Tablet	Oral	Purdue Pharma	1979-12-31	2002-07-30
Vica-cet	Magnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1)	Tablet	Oral	Provision Medical	2015-04-03	Not applicable

International/Other Brands

Analate / Lorisal / Magan / Mobidin / Triact

Categories

UNII

JQ69D454N1

CAS number

18917-89-0

Weight

Average: 298.531
Monoisotopic: 298.03277995

Chemical Formula

C₁₄H₁₀MgO₆

InChI Key

MQHWFIOJQSCFNM-UHFFFAOYSA-L

InChI

InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2

IUPAC Name

magnesium(2+) ion bis(2-hydroxybenzoate)

SMILES

[Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O

Pharmacology

Indication

Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain

Pharmacodynamics

Not Available

Mechanism of action

Most NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.

Target	Actions	Organism
AProstaglandin G/H synthase 2	inhibitor	Humans
AProstaglandin G/H synthase 1	inhibitor	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Pathway	Category
Magnesium Salicylate Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction
(R)-warfarin	The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with (R)-warfarin.
(S)-Warfarin	The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with (S)-Warfarin.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid	The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazole	The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 1-benzylimidazole.
1alpha-Hydroxyvitamin D5	The serum concentration of Magnesium salicylate can be increased when it is combined with 1alpha-Hydroxyvitamin D5.
2,5-Dimethoxy-4-ethylamphetamine	The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine	The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3-Aza-2,3-Dihydrogeranyl Diphosphate	Magnesium salicylate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
4-Bromo-2,5-dimethoxyamphetamine	The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarin	The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with 4-hydroxycoumarin.

Food Interactions

Not Available

References

Synthesis Reference

Satishchandra P. Patel, Vinayak T. Bhalani, "Solid choline magnesium salicylate composition and method of preparing same." U.S. Patent US5043168, issued May, 1954.

US5043168

General References

Not Available

External Links

Human Metabolome Database: HMDB0015469
KEGG Compound: C07995
PubChem Compound: 54684589
PubChem Substance: 46508713
ChemSpider: 58278
ChEBI: 6640
ChEMBL: CHEMBL2106755
PharmGKB: PA450300
Wikipedia: Magnesium_salicylate

Clinical Trials

Clinical Trials: Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Caraco Pharmaceutical Labs
CVS Pharmacy
Ivax Pharmaceuticals
Key Co.
Novartis AG
Palmetto Pharmaceuticals Inc.
Qualitest
US Pharmaceutical Corp.

Dosage forms

Form	Route	Strength
Tablet	Oral	325 mg
Tablet	Oral	580 mg/1
Tablet, film coated	Oral	580 mg/1
Tablet, coated	Oral
Capsule	Oral	580 mg/1
Tablet	Oral	650 mg
Tablet, film coated	Oral
Tablet, coated	Oral	467 mg/1
Tablet	Oral

Prices

Unit description	Cost	Unit
Tricosal 1000 mg tablet	1.23USD	tablet
Choline mag trisal 1 gm tablet	1.15USD	tablet
Choline mag trisal 750 mg tablet	0.81USD	tablet
Novasal 600 mg tablet	0.75USD	tablet
Choline mag trisal 500 mg tablet	0.64USD	tablet
Doan's ex strength 580 mg tablet	0.22USD	tablet
CVS Pharmacy backache rlf 580 mg caplet	0.18USD	caplet
Doan's regular 325 mg tablet	0.18USD	tablet
Keygesic-10 650 mg tablet	0.05USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0686 mg/mL	ALOGPS
logP	2.86	ALOGPS
logP	1.98	ChemAxon
logS	-3.6	ALOGPS
pKa (Strongest Acidic)	2.79	ChemAxon
pKa (Strongest Basic)	-6.3	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	60.36 Å²	ChemAxon
Rotatable Bond Count	2	ChemAxon
Refractivity	46.13 m³·mol^-1	ChemAxon
Polarizability	12.38 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.5741
Blood Brain Barrier	+	0.829
Caco-2 permeable	+	0.5941
P-glycoprotein substrate	Non-substrate	0.6758
P-glycoprotein inhibitor I	Non-inhibitor	0.9704
P-glycoprotein inhibitor II	Non-inhibitor	0.9768
Renal organic cation transporter	Non-inhibitor	0.8975
CYP450 2C9 substrate	Non-substrate	0.7872
CYP450 2D6 substrate	Non-substrate	0.9101
CYP450 3A4 substrate	Non-substrate	0.7282
CYP450 1A2 substrate	Non-inhibitor	0.8837
CYP450 2C9 inhibitor	Non-inhibitor	0.5705
CYP450 2D6 inhibitor	Non-inhibitor	0.9113
CYP450 2C19 inhibitor	Non-inhibitor	0.8537
CYP450 3A4 inhibitor	Non-inhibitor	0.9421
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9021
Ames test	Non AMES toxic	0.9695
Carcinogenicity	Non-carcinogens	0.8587
Biodegradation	Ready biodegradable	0.8277
Rat acute toxicity	2.3552 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.952
hERG inhibition (predictor II)	Non-inhibitor	0.9555

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST): Not Available
Spectra: Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Benzene and substituted derivatives
Sub Class: Benzoic acids and derivatives
Direct Parent: Salicylic acids
Alternative Parents: Benzoic acids / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic salts
show 2 more
Substituents: Salicylic acid / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Carboxylic acid salt / Monocarboxylic acid or derivatives / Carboxylic acid
show 7 more
Molecular Framework: Not Available
External Descriptors: benzenes, carbonyl compound (CHEBI:6640)

Targets

Details1. Prostaglandin G/H synthase 2

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name: PTGS2
Uniprot ID: P35354
Uniprot Name: Prostaglandin G/H synthase 2
Molecular Weight: 68995.625 Da

References

Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163]
Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733]
Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473]
Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270]

Details2. Prostaglandin G/H synthase 1

Kind: Protein
Organism: Humans
Pharmacological action: Yes
Actions: Inhibitor

General Function: Prostaglandin-endoperoxide synthase activity
Specific Function: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name: PTGS1
Uniprot ID: P23219
Uniprot Name: Prostaglandin G/H synthase 1
Molecular Weight: 68685.82 Da

References

Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879]
Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771]
Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445]
Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818]

Carriers

Details1. Serum albumin

Kind: Protein
Organism: Humans
Pharmacological action: No

General Function: Toxic substance binding
Specific Function: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name: ALB
Uniprot ID: P02768
Uniprot Name: Serum albumin
Molecular Weight: 69365.94 Da

References

Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [PubMed:18436441]

Drug created on July 08, 2007 11:04 / Updated on March 11, 2019 19:37

Magnesium salicylate

Identification

Structure for Magnesium salicylate (DB01397)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

Carriers

References